FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
FAST NEWS: Ascletis Pharma Files to Sell Ritonavir in Four European Countries
The latest: Ascletis Pharma Inc. (1672.HK) announced on Sunday that it has submitted marketing authorization applications for its oral ritonavir 100 mg film-coated tablets in Germany, France, Ireland and the…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
